miRNA targets are an area of expanding interest. This incisive report gives you the details.!--h2>
The focus of this GEN Market & Tech Analysis report is to frame the translation of microRNAs from research toward therapeutics.
Highlights of this report:
MicroRNA modulation in vivo can effect therapeutic outcomes, and this is an area of expanding interest—therapeutic modulation of miRs as a treatment strategy for disease.
Indeed, the increasing associations of microRNA signatures with specific physiological and pathological situations is driving the interest in this class of molecules as potential biomarkers but also brings forth the possibility of miR modulation in vivo, with miR mimics with potential therapeutic value in treating disease.
Specific miRs have been therapeutically addressed thusfar in preclinical studies, and this report describes these.
Furthermore, there are clinical studies being initiated and this report presents this landscape.
This report suggests that a very small subset of these signatures/associations are being pursued in the therapeutics realm, and opens the possibility of many more miRs entering preclinical testing in various disease areas we’ve presented and discussed in our reports.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at [email protected].